ESC Premium Access

Lipid-lowering agents - New perspectives

Event: ESC CONGRESS 2016
Topic: Drug therapy
Session type: Moderated Posters
Date: 30 August 2016
Time: 15:35 - 16:25

Congress Session

6 presentations in this session

Effect of K-877, a potent and selective PPAR alpha modulator (SPPARM alpha), on postprandial hyperlipidemia in dyslipidemic patients: a randomized cross-over study

Speaker: Professor S. Yamashita (Izumisano, JP)

A multi-regional, randomized evaluation of the lipid-modifying efficacy and tolerability of anacetrapib added to ongoing statin therapy in patients with hypercholesterolemia or low HDL-C

Speaker: Doctor S. Shah (Rahway, US)

Comparative efficacy of ezetimibe plus simvastatin combined therapy vs. simvastatin monotherapy for individuals with reduced estimated glomerular filtration rate

Speaker: Doctor M. Blazing (Durham, US)

Clinical tolerability and safety profile of CER-001, a novel bio-engineered pre-beta HDL-mimetic, across the clinical development programs

Speaker: Professor A. Corsini (Milan, IT)

Effect of pcsk9 antibodies on neurocognitive outcomes and improved survival in patients at higher risk: a meta-analysis of randomised controlled trials

Speaker: Doctor M. Kolodziejczak (Bydgoszcz, PL)

Dose-response relationship between proton pump inhibitor use and associated risk of myocardial infarction: a nationwide cohort study

Speaker: Doctor T. Sehested (Copenhagen, DK)

6 speakers from this session

Professor Shizuya Yamashita

Rinku General Medical Center , Izumisano (Japan)
0 follower

Doctor Sukrut Shah

, Rahway (United States of America)
0 follower

Doctor Michael Blazing

Duke Clinical Research Institute, Durham (United States of America)
0 follower

Professor Alberto Corsini

University of Milan - Department of Pharmacological Sciences and Bio, Milan (Italy)
0 follower

Doctor Michalina Kolodziejczak

Antoni Jurasz University Hospital No 1, Bydgoszcz (Poland)
0 follower

Doctor Thomas Steen Gyldenstierne Sehested

Herlev and Gentofte Hospital, Copenhagen (Denmark)
0 follower

This platform is supported by

logo Novo Nordisk